Publications / Research

Published

Lao, Chunhuan; van Dantzig, Philippa; Rabindranath, Kannaiyan; White, Douglas; Lawrenson, Ross. Treatment Patterns for End-Stage Kidney Failure in Patients With Systemic Lupus Erythematous. JCR: Journal of Clinical Rheumatology 30(5):p 183-187, August 2024. | DOI: 10.1097/RHU.0000000000002088

Taylor W, Dalbeth N, Kain T, White D, Grainger R, Quincey V, Time to start disease modifying drugs for adults with seropositive rheumatoid arthritis: results of the first year of the national New Zealand Rheumatology Association (NZRA) audit, NZMJ, 2024, In Press

Kristensen L, Keiserman M, Papp K, McCasland L, White D, Carter K, Lippe R, Photowala H, Drogaris L, Soliman A, Chen M, Byron Padilla, Behrens F, Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results From the Phase 3 KEEPsAKE 1 Randomized Clinical Trial, Rheumatology & Therapy. 2024 Mar 18. doi: 10.1007/s40744-024-00654-5. PMID: 38498141.

van Dantzig P, Quincey V, Kurz J, Ming C, Kamalaksha S, White D, Epidemiology of Giant Cell Arteritis in Waikato, Aotearoa New Zealand. N Z Med J. 2024 Mar 22;137(1592):14-21. doi: 10.26635/6965.6379.

van Dantzig P, White D, Kurz J, Ming C, Kamalaksha S, Quincey V, Performance of a Fast-Track Pathway for Giant Cell Arteritis in Waikato, Aotearoa New Zealand, N Z Med J. 2024 Mar 22;137(1592):31-42. doi: 10.26635/6965.6376.

Arad U, Werren C, White D, Paraneoplastic sacroiliitis, BMJ Case Reports, 2023;16:e252572. doi:10.1136/bcr-2022- 252572

White D, Poppelwell D, Impact of a non-medical switch from tocilizumab to upadacitinib in a cohort of patients with rheumatoid arthritis in routine clinical practice, NZMJ, 2023, Aug 25;136(1581):74-78.

Lao C, White D, Rabindranath K, Van Dantzig P, Foxall D, Lawrenson R, Mortality and causes of death in systemic lupus erythematosus in New Zealand: A population-based study, Rheumatology (Oxford), 2023, 10.1093/rheumatology/kead427

Lao C, White D, Rabindranath K, Van Dantzig P, Foxall D, Lawrenson R, Prevalence and outcomes of end-stage kidney disease in patients with systemic lupus erythematous: a population-based study, Rheumatology International, 2023 Aug 14. doi: 10.1007/s00296-023-05409-z

Lao C, White D, Rabindranath K, Van Dantzig P, Foxall D, Aporosa A, et al. Incidence and prevalence of systemic lupus erythematosus in New Zealand from the national administrative datasets. Lupus. 2023;0(0):09612033231182203.

Kim B, Boukebous B, White D, Baker JF. Septic arthritis of the native hip joint: a multi-pattern, multi-outcome disease. European Journal of Orthopaedic Surgery & Traumatology. 2023.

Harris D, Frampton C, Patel S, White D, Arad U. Acute calcium pyrophosphate crystal arthritis is associated with an increased rate of hip and knee joint surgery. Rheumatology. 2023.

Padala SD, Lao C, Solanki K, White D. Direct and indirect health-related costs of systemic sclerosis in New Zealand. International journal of rheumatic diseases. 2022
;n/a(n/a).

Treharne GJ, Johnstone G, Fletcher BD, Lamar RSM, White D, Stebbings S, et al. Fears about COVID-19 and perceived risk among people with rheumatoid arthritis or ankylosing spondylitis following the initial lockdown in Aotearoa New Zealand. Musculoskeletal Care. 2022;20(2):290-8.

Silva C, Solanki K, White D. The relationship between smoking, Raynaud’s phenomenon, digital ulcers, and skin thickness in the Waikato Systemic Sclerosis cohort. Rheumatology and Immunology Research. 2022;3(2):84-9.

McManus EJ, Phillips MCL, Schepel J, Quincey V, Doube A, White D, et al. Neurological manifestations in rheumatological disease, a case series. Neuroimmunology Reports. 2022;2:100075.

Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, et al. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology. 2022.

Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology. 2022.

Solanki KK, Lamont D, White DHN. A Rare Presentation of Renal Impairment in Diffuse Cutaneous Systemic Sclerosis. JCR: Journal of Clinical Rheumatology. 2021;27(8S):S844.

Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Annals of the rheumatic diseases. 2021:annrheumdis-2021-221019.

Johnstone G, Treharne GJ, Fletcher BD, Lamar RSM, White D, Harrison A, et al. Mental health and quality of life for people with rheumatoid arthritis or ankylosing spondylitis in Aotearoa New Zealand following the COVID-19 national lockdown. Rheumatology International. 2021;41(10):1763-72.

Lao C, Lees D, Patel S, White D, Lawrenson R. Length of Hospital Stay for Osteoarthritic Primary Hip and Knee Replacement Surgeries in New Zealand. International Journal of Environmental Research and Public Health. 2019;16(23):4789.

Lao C, Lees D, Patel S, White D, Lawrenson R. Geographical and ethnic differences of osteoarthritis-associated hip and knee replacement surgeries in New Zealand: a population-based cross-sectional study. BMJ open. 2019;9(9):e032993.

White D, Lao C, Williams L, Lawrenson R, Dalbeth N, The costs associated with ankylosing spondylitis/axial spondyloarthritis in Aotearoa/New Zealand. NZMJ, 2019, 132, 1506.

Benham H, Rutherford M, Kirby S, Stebbings S, White D, Sim D, et al. Treat-to-target in rheumatoid arthritis: Evaluating the patient perspective using the Patient Opinion Real-Time Anonymous Liaison system: The RA T2T PORTAL study. International journal of rheumatic diseases. 2019;0(0).

Solanki KK, Al-Majmuei M, White DHN. High Prevalence of Antithyroid Antibodies in a New Zealand Cohort of Patients With Systemic Sclerosis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2018.

Roberts RL, Wallace MC, Harrison A, White D, Dalbeth N, Stamp LK, et al. Association of Crohn’s disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. PeerJ. 2018.

Kamalaksha S, White DHN, Solanki KK. Significance of combined anti-CCP antibodies and rheumatoid factor in a New Zealand cohort of patients with systemic sclerosis. International journal of rheumatic diseases. 2018;21(7):1430-5.

Solanki KK, Hor C, Chang WSJ, Frampton C, White DHN. Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis. International journal of rheumatic diseases. 2017:n/a-n/a.

Ooi C, Solanki K, Lao C, Frampton C, White D. Mortality in the Waikato Hospital Systemic Sclerosis Cohort. International journal of rheumatic diseases. 2017:n/a-n/a.

White DH, Coltman G. A Digital Vascular Malformation Masquerading as Synovitis. Arthritis & rheumatology (Hoboken, NJ). 2016;68(6):1391.

Stamp LK, Haslett J, Frampton C, White D, Gardner D, Stebbings S, et al. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. Internal medicine journal. 2016;46(9):1075-80.

Phipps-Green AJ, Merriman ME, Topless R, Altaf S, Montgomery GW, Franklin C, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Annals of the rheumatic diseases. 2016;75(1):124-30.

Ogdie A, Taylor WJ, Neogi T, Fransen J, Jansen TL, Ralph Schumacher H, et al. Performance of Ultrasound in the Diagnosis of Gout in a Multi-Center Study: Comparison with Monosodium Urate Crystal Analysis as the Gold Standard. Arthritis & rheumatology (Hoboken, NJ). 2016.

Jade J, Chung K, Arendse M, Hussain Z, White D. Neuro-Behçet’s disease presenting with tumour-like lesions and responding to rituximab. Journal of Clinical Neuroscience. 2016.

de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, et al. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis care & research. 2016;68(5):667-72.

White D, Solanki K, Quincey V, Minett A, Tam G, Doube A, et al. Development of a Multidimensional Additive Points System for Determining Access to Rheumatology Services. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2015;21(5):239-43.

Ip K, Hartley L, Solanki K, White D. Retention on anti-tumour necrosis factor therapy: the Waikato experience. The New Zealand medical journal. 2015;128(1415):34-40.

Chang WS, Schollum J, White DH, Solanki KK. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand. Clinical rheumatology. 2015;34(11):1921-7.

Harrison AA, Badenhorst C, Kirby S, White D, Athens J, Stebbings S. Comparison of rates of referral and diagnosis of axial spondyloarthritis before and after an ankylosing spondylitis public awareness campaign. Clinical rheumatology. 2014;33(7):963-8.

Al Aranji G, White D, Solanki K. Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature. Clinical and experimental rheumatology. 2014;32(2):262-6.

White D, Pahau H, Duggan E, Paul S, Thomas R. Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. BMJ open. 2013;3(7).

Roberts RL, Wallace MC, Jones GT, van Rij AM, Merriman TR, Harrison A, et al. Prevalence of HLA-B27 in the New Zealand population: effect of age and ethnicity. Arthritis research & therapy. 2013;15(5):R158.

Rasheed H, Phipps-Green A, Topless R, Hollis-Moffatt JE, Hindmarsh JH, Franklin C, et al. Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption. Arthritis research & therapy. 2013;15(6):R177.

Plunkett M, Lamont D, Brooker J, White D. Relapsing polychondritis: response to tocilizumab and association with colitis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2013;19(7):415-7.

White D, Munroe S. Clinical image: crystal arthritis induced by intraarticular corticosteroid. Arthritis and rheumatism. 2011;63(8):2539.

White DH, Chapman PT, O’Donnell JL, James J, Frampton C, Stamp LK. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Internal medicine journal. 2010;40(8):561-

Jones PB, White D. Reappraisal of the clinical use of le unomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatology: Research and Reviews. 2010;2:53-71.

White DH, Lynskey NV, Jones PB. Leflunomide use in New Zealand. A national prospective post-marketing study. Internal medicine journal. 2009;39(2):95-102.

White DH, Faull K, Jones PB. An exploratory study of long-term health outcomes following an in-patient multidisciplinary program for people with fibromyalgia syndrome. International journal of rheumatic diseases. 2009;12(1):52-6.

White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. The New Zealand medical journal. 2006;119(1240):U2125.

Kristensen L, Keiserman M, Papp K, McCasland L, White D, Carter K, Lippe R, Photowala H, Drogaris L, Soliman A, Chen M, Byron Padilla, Behrens F, Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results From the Phase 3 KEEPsAKE 1 Randomized Clinical Trial, Rheumatology & Therapy. 2024, In Press

van Dantzig P, Quincey V, Kurz J, Ming C, Kamalaksha S, White D, Epidemiology of Giant Cell Arteritis in Waikato, Aotearoa New Zealand. New Zealand Medical Journal. In Press

van Dantzig P, White D, Kurz J, Ming C, Kamalaksha S, Quincey V, Performance of a Fast-Track Pathway for Giant Cell Arteritis in Waikato, Aotearoa New Zealand, New Zealand Medical Journal. In Press

Arad U, Werren C, White D, Paraneoplastic sacroiliitis, BMJ Case Reports, 2023;16:e252572. doi:10.1136/bcr-2022- 252572

White D, Poppelwell D, Impact of a non-medical switch from tocilizumab to upadacitinib in a cohort of patients with rheumatoid arthritis in routine clinical practice, NZMJ, 2023, Aug 25;136(1581):74-78.

Lao C, White D, Rabindranath K, Van Dantzig P, Foxall D, Lawrenson R, Mortality and causes of death in systemic lupus erythematosus in New Zealand: A population-based study, Rheumatology (Oxford), 2023, 10.1093/rheumatology/kead427

Lao C, White D, Rabindranath K, Van Dantzig P, Foxall D, Lawrenson R, Prevalence and outcomes of end-stage kidney disease in patients with systemic lupus erythematous: a population-based study, Rheumatology International, 2023 Aug 14. doi: 10.1007/s00296-023-05409-z

Lao C, White D, Rabindranath K, Van Dantzig P, Foxall D, Aporosa A, et al. Incidence and prevalence of systemic lupus erythematosus in New Zealand from the national administrative datasets. Lupus. 2023;0(0):09612033231182203.

Kim B, Boukebous B, White D, Baker JF. Septic arthritis of the native hip joint: a multi-pattern, multi-outcome disease. European Journal of Orthopaedic Surgery & Traumatology. 2023.

Harris D, Frampton C, Patel S, White D, Arad U. Acute calcium pyrophosphate crystal arthritis is associated with an increased rate of hip and knee joint surgery. Rheumatology. 2023.

Padala SD, Lao C, Solanki K, White D. Direct and indirect health-related costs of systemic sclerosis in New Zealand. International journal of rheumatic diseases. Dec;25(12):1386-1394. 2022 doi: 10.1111/1756-185X.14433.

Treharne GJ, Johnstone G, Fletcher BD, Lamar RSM, White D, Stebbings S, et al. Fears about COVID-19 and perceived risk among people with rheumatoid arthritis or ankylosing spondylitis following the initial lockdown in Aotearoa New Zealand. Musculoskeletal Care. 2022;20(2):290-8.

Silva C, Solanki KK, White DHN. The relationship between smoking, Raynaud’s phenomenon, digital ulcers, and skin thickness in the Waikato Systemic Sclerosis cohort. Rheumatology and Immunology Research. 2022;3(2):84-9.

McManus EJ, Phillips MCL, Schepel J, Quincey V, Doube A, White D, et al. Neurological manifestations in rheumatological disease, a case series. Neuroimmunology Reports. 2022;2:100075.

Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, et al. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology. 2022.

Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology. 2022.

Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Annals of the rheumatic diseases. 2021:annrheumdis-2021-221019.

Solanki KK, Lamont D, White DHN. A Rare Presentation of Renal Impairment in Diffuse Cutaneous Systemic Sclerosis. JCR: Journal of Clinical Rheumatology. 2021;27(8S):S844.

Johnstone G, Treharne GJ, Fletcher BD, Lamar RSM, White D, Harrison A, et al. Mental health and quality of life for people with rheumatoid arthritis or ankylosing spondylitis in Aotearoa New Zealand following the COVID-19 national lockdown. Rheumatology International. 2021;41(10):1763-72.

Lao C, Lees D, Patel S, White D, Lawrenson R. Length of Hospital Stay for Osteoarthritic Primary Hip and Knee Replacement Surgeries in New Zealand. International Journal of Environmental Research and Public Health. 2019;16(23):4789.

Lao C, Lees D, Patel S, White D, Lawrenson R. Geographical and ethnic differences of osteoarthritis-associated hip and knee replacement surgeries in New Zealand: a population-based cross-sectional study. BMJ open. 2019;9(9):e032993.

Benham H, Rutherford M, Kirby S, Stebbings S, White DHN, Sim D, Harrison AA. Treat to target in rheumatoid arthritis: evaluating the patient perspective using the Patient Opinion Real-Time Anonymous Liaison system: the RA T2T PORTAL study. Int J Rheum Dis. 2019 May;22(5):874-879. doi: 10.1111/1756-185X.13514.

Solanki KK, al-Majmuei M, White DHN. High Prevalence of anti-thyroid antibodies in a New Zealand cohort of patients with Systemic Sclerosis, J Clin Rheumatol. 2018 Aug;24(5):264-271. doi: 10.1097/RHU.0000000000000703.

Ooi C, Solanki KK, Lao C, Frampton C, White DHN, Mortality in the Waikato Hospital Systemic Sclerosis Cohort, International Journal of Rheumatic Diseases, 2018 Jan;21(1):253-260. doi: 10.1111/1756-185X.13111. Epub 2017 Jun 4.

Solanki KK, Hor C, Chang WSJ, Frampton C, White DHN. Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis. Int J Rheum Dis. 2017 Jun;20(6):767-773. doi: 10.1111/1756-185X.13049.

White DHN, Kocijan R. Rheumatoid Arthritis and Spondyloarthritis. In: Pietschmann P, editor. Principles of Osteoimmunology: Molecular Mechanisms and Clinical Applications. Cham: Springer International Publishing; 2016. p. 181-215.

White DHN, Coltman G. A Digital Vascular Malformation Masquerading as Synovitis. Arthritis & rheumatology (Hoboken, NJ) 2016;68:1391

Stamp LK, Haslett J, Frampton C, White D, Gardner D, Stebbings S, et al. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. Internal medicine journal 2016;46:1075-80.

Phipps-Green AJ, Merriman ME, Topless R, Altaf S, Montgomery GW, Franklin C, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Annals of the rheumatic diseases 2016;75:124-30.

Ogdie A, Taylor WJ, Neogi T, Fransen J, Jansen TL, Ralph Schumacher H, et al. Performance of Ultrasound in the Diagnosis of Gout in a Multi-Center Study: Comparison with Monosodium Urate Crystal Analysis as the Gold Standard. Arthritis Rheumatol. 2017 Feb;69(2):429-438. doi: 10.1002/art.39959.

Jade J, Chung K, Arendse M, Hussain Z, White D. Neuro-Behçet’s disease presenting with tumour-like lesions and responding to rituximab. J Clin Neurosci. 2016 Oct;32:139-41. doi: 10.1016/j.jocn.2016.03.020.

de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, et al. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis care & research 2016;68:667-72.

White D, Solanki K, Quincey V, Minett A, Tam G, Doube A, et al. Development of a Multidimensional Additive Points System for Determining Access to Rheumatology Services. Journal of clinical rheumatology, 2015;21:239-43.

Ip K, Hartley L, Solanki K, White D. Retention on anti-tumour necrosis factor therapy: the Waikato experience. The New Zealand medical journal 2015;128:34-40.

Chang WS, Schollum J, White DH, Solanki KK. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand. Clinical Rheumatology 2015;34:1921-7.

Harrison AA, Badenhorst C, Kirby S, White D, Athens J, Stebbings S. Comparison of rates of referral and diagnosis of axial spondyloarthritis before and after an ankylosing spondylitis public awareness campaign. Clinical rheumatology 2014;33:963-8

al Aranji G, White D, Solanki K. Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature. Clinical and experimental rheumatology 2014;32:262-6.

White D, Pahau H, Duggan E, Paul S, Thomas R. Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. BMJ open 2013;3.

Roberts RL, Wallace MC, Jones GT, van Rij AM, Merriman TR, Harrison A, et al. Prevalence of HLA-B27 in the New Zealand population: effect of age and ethnicity. Arthritis research & therapy 2013;15:R158.

Rasheed H, Phipps-Green A, Topless R, Hollis-Moffatt JE, Hindmarsh JH, Franklin C, et al. Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption. Arthritis research & therapy 2013;15:R177

Plunkett M, Lamont D, Brooker J, White D. Relapsing polychondritis: response to tocilizumab and association with colitis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2013;19:415-7.

White D, Munroe S. Clinical image: crystal arthritis induced by intraarticular corticosteroid. Arthritis and rheumatism 2011;63:2539.

White DH, Chapman PT, O’Donnell JL, James J, Frampton C, Stamp LK. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Internal medicine journal 2010;40:561-5.

Jones PB, White D. Reappraisal of the clinical use of le unomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatology: Research and Reviews 2010;2:53-71.

White DH, Lynskey NV, Jones PB. Leflunomide use in New Zealand. A national prospective post-marketing study. Internal medicine journal 2009;39:95-102.

White DH, Faull K, Jones PB. An exploratory study of long-term health outcomes following an in-patient multidisciplinary program for people with fibromyalgia syndrome. International journal of rheumatic diseases 2009;12:52-6.

White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. The New Zealand medical journal 2006;119:U2125.

Posters

White D, Poppelwell D, Impact of a non-medical switch from tocilizumab to upadacitinib in a cohort of patients with rheumatoid arthritis in routine clinical practice – poster presentation at the Australian Rheumatology Association Meeting, Hobart, 2023

Papp K, Soliman AM, Kaufmann C, Barcomb L, Wang Z, White D, et al. 33236 Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from 2 phase III trials. Journal of the American Academy of Dermatology. 2022;87(3):AB174.

Lao C, Lees D, White D, Lawrenson R. FRI0514 USE OF OPIATE FOR HIP AND KNEE OSTEOARTHRITIS BEFORE AND AFTER JOINT REPLACEMENT SURGERY. Annals of the rheumatic diseases. 2020;79(Suppl 1):856-.

Kamalaksha S, White D, Quincey V. 254. PERFORMANCE OF A FAST TRACK PATHWAY FOR THE DIAGNOSIS OF GIANT CELL ARTERITIS (GCA) AND USING COLOUR DUPLEX ULTRASOUND (CDUS) – NEW ZEALAND EXPERIENCE. Rheumatology. 2019;58(Supplement_2).

White D H, Ip K, Hartley L & Solanki K (2014). 5 Year survival on anti-TNF therapy: the Waikato experience. Poster session presented at the meeting of the New Zealand Rheumatology Association Annual Meeting. Dunedin.

Ip K, Hartley L, Solanki K, & White D H(2014). Changes in pre-biologic screening over time: the Waikato experience. Poster session presented at the meeting of the New Zealand Rheumatology Association Annual Meeting. Dunedin.

Liao S, Taylor T, Steele R, & White DH (2014). The ANA negative, dsDNA positive conundrum: A review and comparison of ELISA and Farr assays. Poster session presented at the meeting of the New Zealand Rheumatology Association Annual Meeting. Dunedin.

White D H, Doube A, Quincey V, Solanki K, Sawyers S, Tam G, Minett A & Naden R (2014). Development of the Waikato Rheumatology Referral Triage Process. Poster session presented at the meeting of Internal Medicine Journal. Hobart. doi:10.1111/imj.12426

Solanki K, Hor C, Schollum J, Campbell R, Empson M, Sole T, Petrie P, White D H(2014). Clinical utility of Salt & Pepper Skin changes in the Waikato Hospital Systemic Sclerosis Cohort. Poster session presented at the meeting of Clinical and Experimental Rheumatology. Rome. Retrieved from http://www.clinexprheumatol.org/a.asp?IDArchivio=156

Chang W, Schollum J, Campbell R, Empson M, Sole T, Petrie J., White D& Solanki, K. (2014). Review of the Antibody Profile of the Patients in the Waikato Systemic Sclerosis Clinic. Poster session presented at the meeting of Clinical and Experimental Rheumatology. Rome. Retrieved from http://www.clinexprheumatol.org/a.asp?IDArchivio=156

al Aranji G, Solanki K & White D,Quality of Referrals to the Rheumatology Department at Waikato Hospital. New Zealand Rheumatology Association Annual Scientific Meeting, Hamilton, 1-4 August 2013.

White D, Doube A, Quincey V, Solanki K, Sawyers S, Tam G, Minnett A, Armstrong J & Naden R, Development of the Waikato Rheumatology Referral Triage Process. New Zealand Rheumatology Association Annual Scientific Meeting, Hamilton, 1-4 August 2013.

Wales S, Holmes T & White D, A pilot hydrotherapy program for people with ankylosing spondylitis. New Zealand Rheumatology Association Annual Scientific Meeting, Hamilton, 1-4 August 2013.

Ip K, Schollum A, Petrie J, Sole T, White D& Solanki K, Significance of IgG Levels in the Waikato Systemic Sclerosis Cohort. New Zealand Rheumatology Association Annual Scientific Meeting, Hamilton, 1-4 August 2013.

Chang W, Schollum A, Campbell R, Empson M, Sole T, Petrie J, White D& Solanki K, Review of the autoantibody profile of patients in the Waikato Systemic Sclerosis Cohort. New Zealand Rheumatology Association Annual Scientific Meeting, Hamilton, 1-4 August 2013.

al Majmeui M, Schollum A, Quincey V, Jones P, Doube A, Sole T, Petrie J, White D& Solanki K, High prevalence of anti-thyroid antibodies in a New Zealand cohort of patients with Systemic Sclerosis. Asia Pacific League of Associations for Rheumatology Annual Scientific Meeting, Oman, 10-14 September 2012.

White D, Chen YS, Pahau H, Duggan E & Thomas R, Clinical features of disease severity and body mass index predict outcome at 6 months in a cohort of patients with early rheumatoid arthritis. Australian & New Zealand Rheumatology Associations Scientific Meeting, Wellington, 3-6 May 2009.

White D, Darlington D & Doube A, Prevalence of mechanical back dysfunction in a convenience cohort of New Zealand Europeans with self-reported fibromyalgia. Australian & New Zealand Rheumatology Associations Scientific Meeting, Wellington, 3-6 May 2009.

Bradbury LA, Benham H, Hutton I, Lewington M, Turner M, McFarlane J, Pettet E, Warner J, White D& Brown M. Establishment of an Ankylosing Spondylitis Specialist Clinic. Princess Alexandra Hospital Week 2009.

Studies

GCP Training

Pfizer TransCelerate

Date Started: Feb 28, 2018 – Date Completed: Feb 28, 2018

Research Experience

Industry Research Experience
I have been involved with 50 clinical trials, 40 as Principal investigator and 10 as sub-investigator. These have been a mixture of Phase II, III, IV studies in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, fibromyalgia, giant cell arteritis, systemic sclerosis, osteoarthritis and gout as listed below:

NCT00413699
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
10039073

NCT01039688
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
10039073

NCT01194414
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
RHEUMATOID ARTHRITIS

NCT01606761
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
ARTHRITIS, RHEUMATOID

NCT01651936
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
Rheumatoid arthritis

NCT01808118
Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
http://ontology.abbvienet.com/indications/abbvie#ABIN10000156/urn:x-evn-master:AbbVieIndications

NCT01960855
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
http://ontology.abbvienet.com/indications/abbvie#ABIN10000154/urn:x-evn-master:AbbVieIndications

NCT02049138
An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis
http://ontology.abbvienet.com/indications/abbvie#ABIN10000154/urn:x-evn-master:AbbVieIndications

NCT02092467
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
10039073

NCT02349451
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)
http://ontology.abbvienet.com/indications/abbvie#ABIN10000212/urn:x-evn-master:AbbVieIndications

NCT02446912
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus

NCT02451839
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
Phase NA: http://ontology.abbvienet.com/indications/abbvie#ABIN10000154/urn:x-evn-master:AbbVieIndications

NCT02480153
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
10039073

NCT02629159
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
http://ontology.abbvienet.com/indications/abbvie#ABIN10000154/urn:x-evn-master:AbbVieIndications

NCT02706873
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
http://ontology.abbvienet.com/indications/abbvie#ABIN10000154/urn:x-evn-master:AbbVieIndications

NCT03104374
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)
http://ontology.abbvienet.com/indications/abbvie#ABIN10000212/urn:x-evn-master:AbbVieIndications

NCT03104400
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
http://ontology.abbvienet.com/indications/abbvie#ABIN10000212/urn:x-evn-master:AbbVieIndications

NCT03178487
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
http://ontology.abbvienet.com/indications/abbvie#ABIN10000156/urn:x-evn-master:AbbVieIndications

NCT03671148
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
http://ontology.abbvienet.com/indications/abbvie#ABIN10000212/urn:x-evn-master:AbbVieIndications

NCT03675308
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
http://ontology.abbvienet.com/indications/abbvie#ABIN10000212/urn:x-evn-master:AbbVieIndications

NCT03725202
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
http://ontology.abbvienet.com/indications/abbvie#ABIN10000148/urn:x-evn-master:AbbVieIndications

NCT03978520
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
http://ontology.abbvienet.com/indications/abbvie#ABIN10000160/urn:x-evn-master:AbbVieIndications

NCT04169373
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
http://ontology.abbvienet.com/indications/abbvie#ABIN10000158/urn:x-evn-master:AbbVieIndications

NCT04972968
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
http://ontology.abbvienet.com/indications/abbvie#ABIN10000450/urn:x-evn-master:AbbVieIndications

NCT05559580
A Study in People With Systemic Sclerosis to Test Whether BI 685509 Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
10021425

NCT01808118
Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
Phase III: Axial Spondyloarthritis

NCT02706873
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
Phase III: Rheumatoid Arthritis

NCT02049138
An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis
Phase II: Rheumatoid Arthritis

NCT01960855
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
Phase II: Rheumatoid Arthritis

NCT02706873
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
Phase III: Rheumatoid Arthritis

NCT01493531
Combining Lesinurad With Allopurinol in Inadequate Responders
Phase III: Gout

NCT01510158
Combining Lesinurad With Allopurinol in Inadequate Responders
Phase III: Gout

NCT02187159
Treatment of Pain Associated With Fibromyalgia
Phase III: Pain Associated With Fibromyalgia

NCT02234583
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Phase III: Pain Associated With Fibromyalgia

NCT03104374
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)
Phase III: Psoriatic Arthritis

NCT03104400
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Phase III: Psoriatic Arthritis

NCT02429895
A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197
Phase II: Psoriatic Arthritis

NCT01925768
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Phase III: Psoriatic Arthritis

NCT01172938
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Phase III: Psoriatic Arthritis

NCT02022930
Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis
Phase III: Osteoarthritis of the Knee

NCT02446912
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Phase III: Active Systemic Lupus Erythematosus

NCT01488708
On Open-Label Study in Participants With Systemic Lupus Erythematosus
Phase III: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease

NCT01205438
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Phase III: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease

NCT02283762
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
Phase II: Scleroderma, Systemic

NCT02531633
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Phase III: Giant Cell Arteritis

NCT03178487
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
Phase II: Ankylosing Spondylitis (AS)

NCT03675308
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Phase III: Psoriatic Arthritis

NCT03671148
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Phase III: Psoriatic Arthritis (PsA)